European Archives - Page 863 of 1260 - European Medical Journal

This site is intended for healthcare professionals

Continue
1 Mins
1 Aug 2019

Tagraxofusp is a Novel Targeted Therapy Directed to CD123

Blastic plasmocytoid dendritic cell neoplasm (BPDCN), a rare, highly aggressive haematologic malignancy, often with cutaneous and other extramedullary…
12 Mins
1 Aug 2019

Review of the European Hematology Association (EHA) Congress 2019

EHA President Pieter Sonnevel welcomed the 12,614 haematology professionals to the Dutch capital, the largest number of attendees recorded…
August 2019

EMJ Hematology 7.1 2019

EMJ Hematology 7.1 aims to provide you with a detailed review of the event, an account that is perfectly accompanied by a hand-picked selection of…
8 Mins
1 Aug 2019

Rebooting the Myeloma Treatment Programme

Treatment of MM requires a multifaceted approach using a combination of therapies targeting the several pathophysiological pathways involved in the…
1 Mins
1 Aug 2019

Post-Transplant Cyclophosphamide in HLA Matched and Haploidentical Transplant Recipients Receiving Myeloablative Timed Sequential Busulfan Conditioning Regimen: Results of a Phase II Study

The authors report a prospective Phase II trial to assess (a) if post-transplant cyclophosphamide (PTCy) could be safely incorporated in a timed…
12 Mins
1 Aug 2019

EHA 2019 Interviews

Find out more about about the EHA Congress through our interviews with members of the various committees required to help…
3 Mins
1 Aug 2019

Umbilical Cord Blood Donation: An Evolving Lifeline for the Stem Cell Field

Cord blood can be collected and stored from the placenta and umbilical cord following the birth of a new-born. It is replete with haematopoietic stem…
1 Mins
1 Aug 2019

Autologous Dendritic Cell Vaccination to Prevent Progression and Relapse in Multiple Myeloma

Data from the National Cancer Institute showed that 50% of myeloma patients survive past 5 years post-diagnosis. This is encouraging but also warns…
5 Mins
1 Aug 2019

Editor’s Pick: New Insights in β-Thalassaemia

Thalassaemia is a hereditary cause of hypochromic microcytic anaemia resulting from defects in haemoglobin (Hb) production…
2 Mins
1 Aug 2019

Gilteritinib Plus Azacitidine in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukaemia Patients Ineligible for Intensive Induction Chemotherapy: Preliminary Findings from the Safety Cohort

Search of more effective treatment for patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy remains challenging…
We’ve noticed you’re accessing
from North/South America.